Centre should consider traditional Indian medicines for COVID-19: Dr Anbumani Ramadoss

Image
ANI General News
Last Updated : Apr 02 2020 | 6:15 PM IST

Former Health Minister and Rajya Sabha member Dr Anbumani Ramadoss has requested the government to consider traditional Indian medicines for treating COVID-19 patients.

"As a western medical practitioner, I do not see anything wrong in it. When COVID-19 was at the highest level, China used traditional Chinese medicine with western medicine," Anbumani said in a statement.

Anbumani further said the traditional Indian medicine has been helpful to cure and prevent dengue, malaria among others.

"At the same time, there has been a misconception about Siddha among some officials. It has to be changed and the central and state governments should pursue it to control the spread of the pandemic," Anbumani said.

The total number of coronavirus cases in India has climbed to 1965 on Thursday, said the Ministry of Health and Family Welfare.

It was reported on January 28 earlier this year that a Siddha doctor from Tamil Nadu claimed to have formulated a herbal medicine that can cure coronavirus.

Dr Thanikasalam Veni of Rathna Siddha Hospital in Chennai has 25-year of vast experience in field Siddha and Ayurvedic medicines.

Speaking to ANI, he had said: "We have formulated a medicine from an extract of herbs. It is very effective to cure any type of viral fever. Coronavirus has no medicine."

"Our herbal extract medicine is used to treat dengue, multi-organ fever and acute liver fever... our medicine is very effective in treating multi-organ failure in corona fever condition," he said.

The Siddha doctor claimed that the medicine formulated by him along with his team treats infections caused by the virus within 24 to 40 hours.

"When we treated the dengue virus with our medicine, many patients with reduced platelets count, acute liver failure, immunity deficiency and low white blood cell (WBC) were cured within 24-40 hours," said Dr Veni.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 02 2020 | 6:01 PM IST

Next Story